The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Another thing to keep in mind is that some that invest in small cap drug companies don't get involved until successful phase 2 trial has been completed as they consider that to be proof of concept. 4D has obviously already done that with Blautix but I suspect there will be a ramped increase in interest from such investors if/when a successful phase 2 for mrx0518 is completed. Being listed on nasdaq gives the best possible springboard for the future.
Baillie Gifford were the reason I invested here for the 1st time in 2018. I don't know if they participated in the last placing but they did in the 1 before that.
I heard the manager of the Fidelity Special Situations fund make a positive reference to 4D last year but I wasn't sure if they were invested.
Boonco- Did they attract those institutions to invest?
"Many institutions are prohibited from buying AIM stocks because of low market cap. They won’t even look at AIM. Hence Nasdaq."
Crl, you're right that some funds don't buy small market cap listed in UK but others do, off the top of my head Fidelity, Baillie Gifford and Ruffer all hold 4D. It's also not the reason why 4D listed on Nasdaq. 4D listed on nasdaq to gain access to the specialist healthcare focused institutions, analysts and investors etc that the UK simply does not have.
yep plenty more to potentially dump
LOL That's not what he said!
Crl123 you say Olivera has sold out I would advise you read the rns simply research
Many institutions are prohibited from buying AIM stocks because of low market cap. They won’t even look at AIM. Hence Nasdaq. Directors could be accused of Insider trading on positive information particularly if close to RNS. There are strict time rules around result RNS’s.
AIM is not the focus of most instis except those with a specialized microcap fund.
Snaffling cheap shares is not that easy for istis in AIM. And some have strict benchmarks too.
Only when the fat lady sings( Oliveira has sold out) can the dust settle here. All up in the air!!
I’d be highly interested if anyone knows how many he has sold to date.
That’s a very good point Sanji. Yes , they are more than likely unable to buy shares atm. They seen very straight individuals are would probably be petrified of advising their friends or another investor to buy right now. Very poor timing for the seller and a great opportunity for those who have the courage to take advantage of a crazy price
I am referring to the directors in case not clear
Also if they have insight into the readouts from the 0518 ongoing it wouldn't look good if they were buying.
They have only ever bought in placings.
It's difficult for UK IIs to buy Aim stocks as they are seen as too risky for the majority of funds.
I imagine US investors are waiting for more data.
If that were the case, word would have inevitably gotten out and friends of friends would be buying shares left, right and centre….but I hope you are right!
Maybe the next RNS that we will see will be notifying us that the shares are suspended due to an offer from Merck.
It just seems very strange to me that these shares are on the market and have not been bought by another large investor or even the directors. If they have been negotiating a buyout with Merck, they wouldn’t be allowed to buy them.